Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949352 | 0.86 | TSHR (0.35) | — | |
| SCHEMBL5948977 | 0.85 | DNM1 (0.38) | ALDH1A1FDPSDNM1OPRM1 | |
| SCHEMBL9949184 | 0.83 | ALDH1A1 (0.35) | SPHK1ALDH1A1CA2MAPK1 | |
| SCHEMBL9950156 | 0.83 | SPHK1 (0.32) | SPHK1ALDH1A1FDPSDNM1 | |
| SCHEMBL9950134 | 0.82 | SPHK1 (0.34) | SPHK1ALDH1A1FDPSDNM1CA2 | |
| SCHEMBL24693228 | 0.81 | DNM1 (0.35) | ALDH1A1FDPSDNM1OPRM1 | |
| SCHEMBL5514697 | 0.81 | DNM1 (0.35) | SPHK1ALDH1A1DNM1OPRM1 | |
| SCHEMBL21558638 | 0.79 | ALDH1A1 (0.34) | ALDH1A1DNM1CA2MAPK1OPRM1 | |
| SCHEMBL9949328 | 0.78 | ALDH1A1 (0.35) | SPHK1ALDH1A1FDPSDNM1CA2 | |
| SCHEMBL9949522 | 0.78 | SPHK1 (0.32) | SPHK1ALDH1A1FDPSDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106943848-B | Carbon dioxide capture system and method of operating a carbon dioxide capture system | 株式会社东芝 | 2021-04-13 | — | — | CN | disclosed |
| US-10864478-B2 | Carbon dioxide capture system and a method of operating a carbon dioxide capture system | KABUSHIKI KAISHA TOSHIBA (JP) | 2020-12-15 | — | — | US | disclosed |
| EP-2705894-B1 | Acid gas absorbent, acid gas removal method and acid gas removal device | TOSHIBA KK (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-20170165603-A1 | CARBON DIOXIDE CAPTURE SYSTEM AND A METHOD OF OPERATING A CARBON DIOXIDE CAPTURE SYSTEM | KABUSHIKI KAISHA TOSHIBA (JP) | 2017-06-15 | — | — | US | disclosed |
| US-9409119-B2 | Acid gas absorbent, acid gas removal method, and acid gas removal device | KABUSHIKI KAISHA TOSHIBA (JP) | 2016-08-09 | — | — | US | disclosed |
| EP-2705894-A1 | Acid gas absorbent, acid gas removal method and acid gas removal device | Kabushiki Kaisha Toshiba (JP) | 2014-03-12 | — | — | EP | disclosed |
| CN-102553395-A | Acid gas absorbent, acid gas removal method and acid gas removal device | TOSHIBA KK | 2012-07-11 | — | — | CN | disclosed |
| US-20120161071-A1 | ACID GAS ABSORBENT, ACID GAS REMOVAL METHOD, AND ACID GAS REMOVAL DEVICE | KABUSHIKI KAISHA TOSHIBA (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2468385-A2 | Acid gas absorbent, acid gas removal method and acid gas removal device | Kabushiki Kaisha Toshiba (JP) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120161071-A1 | ACID GAS ABSORBENT, ACID GAS REMOVAL METHOD, AND ACID GAS REMOVAL DEVICE | ALKBH1, ALKBH3, ALKBH2 | SPHK1 3316/4885ALDH1A1 247/4885FDPS 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.